TerminatedNCT02949232
Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
Medication studyAges 18–70Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 70 years.
- Listed locations
- Antwerp and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 2014
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 42
- Sponsor
- UMC Utrecht
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Belgium, Denmark, Netherlands
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT02949232
- Official title
Show the full official title
Prednisolone Addition for Patients With Recent-onset Psychotic Disorder: the Role of Immune-modulating Strategies in the Treatment of Psychosis
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Antwerp, Belgium · Risskov, Denmark · Sliedrecht, Netherlands
1 more locations
- Utrecht, Netherlands
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is UMC Utrecht.
Does this study involve medication?
Yes. The study involves medication, including Prednisolone and Placebo Oral Tablet.
Who can participate?
Listed age limits: 18 years to 70 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients